Careprost supports eyelash growth by applying bimatoprost 0.03% to the upper eyelid margin. Results develop gradually with consistent daily use.
It is intended for adults seeking longer, thicker, darker-looking eyelashes through a prostamide-related effect on the eyelash growth cycle.
Bimatoprost belongs to the prostamide group of ocular prostaglandin analogues.
Careprost contains bimatoprost 0.03% in an ophthalmic solution supplied as eye drops in a bottle. Bimatoprost is a synthetic prostamide analogue used in ophthalmology. Prostamides are closely related to prostaglandin analogues, but they act through distinct pathways after conversion and tissue interaction.
At the eyelash margin, bimatoprost can prolong the active growth phase of eyelash follicles. In the eye, bimatoprost also increases aqueous humour outflow, which can reduce intraocular pressure. That dual pharmacological profile explains why the same active substance is used in ophthalmic treatment and eyelash enhancement.
The active ingredient is bimatoprost at a concentration of 0.03%. The solution is applied topically to the upper eyelid margin rather than used as a routine eye drop for cosmetic eyelash treatment.
Bimatoprost does not create an instant cosmetic change. It influences the hair cycle, so the visible effect depends on follicle response, regular application, and continued use.
Bimatoprost belongs to the prostamide group of ocular prostaglandin analogues. Its ophthalmic actions include increasing the outflow of aqueous humour and influencing eyelash follicles.
Careprost is intended for adults seeking longer, thicker, darker-looking eyelashes. It is applied topically to the upper eyelid margin, where bimatoprost 0.03% supports the eyelash growth cycle.
The amount used for eyelash treatment is set individually rather than being one fixed amount for every person. The application is topical and limited to the upper eyelid margin.
Apply Careprost once daily, usually in the evening. More frequent application does not accelerate eyelash growth and may increase redness, itching, skin darkening, or other unwanted effects. Applying the liquid to the lower eyelid can increase contact with the surrounding skin and may cause unwanted darkening beneath the eyes.
Contact lenses should be removed before application because preservatives in ophthalmic solutions can remain on soft lenses and contribute to irritation. Allow enough time after application for the solution to dry before replacing lenses.
A missed evening application does not require a double application the next day. Resume the usual daily schedule. Doubling the amount can increase exposure without restoring the missed benefit.
This product may not be suitable if you have inflamed eyes, unexplained changes in vision, substantial eyelid swelling, or an allergy to bimatoprost. Speak with a clinician before use if you have glaucoma, a history of macular oedema, recent eye surgery, or are pregnant or breastfeeding. Extra medical advice is also needed if you use other medicines that lower eye pressure.
Careprost can cause local eye or eyelid reactions. Most reported problems relate to the application site, the surrounding skin, or the ocular surface.
Possible effects include:
The product can also cause hair growth outside the intended lash line if it repeatedly touches the cheek or lower eyelid. Careful application reduces this risk.
Eyelid hyperpigmentation may fade after treatment stops, though the timing varies. Iris darkening is a different issue. Increased brown pigmentation of the iris can be permanent, especially in people with mixed-colour irises. This risk is more relevant when bimatoprost enters the eye repeatedly rather than remaining on the upper eyelid margin.
Stop application and seek urgent medical assessment for eye pain, marked swelling, sudden vision change, pronounced light sensitivity, or a new distortion in vision. These symptoms are not typical cosmetic irritation and can indicate a more significant ocular problem.
Bimatoprost may also affect intraocular pressure. People receiving treatment for glaucoma need coordinated advice from an ophthalmology team because adding or stopping an ocular prostamide can alter pressure management. The EMA product information for bimatoprost ophthalmic preparations describes ocular precautions, pressure effects, and adverse reactions [2].
Bimatoprost appears to extend the anagen phase, which is the active growing phase of the eyelash cycle. A useful way to picture this is a longer growing season for each follicle.
Bimatoprost acts near the eyelash follicles. The precise biological pathway is more complex than simply increasing blood flow, and individual follicle sensitivity differs.
The clinical trial evidence behind bimatoprost eyelash treatment showed improvement in eyelash prominence over a sustained treatment period rather than after a single application [1].
Several avoidable habits can reduce the benefit or increase irritation:
One small detail matters: the bottle tip should remain clean and should not touch the eye or skin. Contact can contaminate the solution and may also make the next application less precise.
Patients with a history of glaucoma sometimes assume that an eye-related product is automatically suitable for them. Bimatoprost can lower intraocular pressure, yet the correct regimen depends on the person’s diagnosis, current drops, eye pressure, and surgical history.
Bimatoprost is the principal evidence-based active substance used for prescription eyelash enhancement. Other eyelash products may rely on conditioning ingredients, peptides, oils, or cosmetic polymers. These categories do not work through the same prostamide mechanism.
| Approach | Main action | Practical limitation |
|---|---|---|
| Bimatoprost ophthalmic solution | Extends the active eyelash growth phase | Requires careful daily application and ocular precautions |
| Peptide or conditioning serum | Conditions the lash fibre and may reduce breakage | Does not have the same established follicle-growth mechanism |
| Cosmetic mascara or fibre product | Adds immediate visual length or volume | Washes off and does not alter the growth cycle |
Bimatoprost is the option with a pharmacological effect on the eyelash follicle. Conditioning products can improve the appearance of existing lashes but should not be described as equivalent to an ocular prostamide.
In clinical practice, doctors usually focus on technique before judging the result. A patient who applies excess liquid to the cheek may develop irritation or skin darkening while seeing little additional lash benefit. Another common issue is stopping after two weeks because the change is not yet visible.
A clinician would also separate cosmetic expectations from eye-health treatment. Careprost may improve lash length, thickness, and darkness, but it does not correct eyelid inflammation, treat an eye infection, or replace glaucoma therapy.
The response should be reviewed over time. Persistent redness, recurrent irritation, or any visual symptom changes the balance between cosmetic benefit and ocular risk. Medsafe provides New Zealand medicine safety information and product data for ophthalmic medicines, including warnings that support careful use of bimatoprost preparations [3].
Careprost contains bimatoprost, a prostamide-related ophthalmic active substance that can influence the eyelash follicle’s growth phase. Conditioning products generally coat or moisturise existing lashes and may reduce breakage, but they do not provide the same pharmacological mechanism. This difference explains why Careprost has ocular precautions that a simple cosmetic conditioner may not have. Product selection should reflect whether the goal is follicle stimulation or temporary lash conditioning. The PubMed-indexed 2010 clinical trial of bimatoprost supports distinguishing pharmacological growth effects from cosmetic conditioning.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The outer lashes looked longer first, then the whole lash line became more noticeable. I had mild redness during the first week, which settled when I used less excess liquid.
I noticed darker and fuller lashes by around week eight. The routine was easy, but I missed several applications while travelling and the progress seemed slower afterward.
I developed itching around one eye and decided not to continue until it was assessed. I did not see a major change in that short period, so the treatment did not feel worthwhile for me.
